Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the
field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues …

Highlights•Albeit their clinical success, ADCs have a relatively narrow therapeutic
index.•Dose-limiting toxicities of ADCs are frequently unrelated to the targeted …

Redox dysregulation originating from metabolic alterations and dependence on mitogenic
and survival signaling through reactive oxygen species represents a specific vulnerability of …

Abstract The European LeukemiaNet (ELN), workpackage 10 (WP10) was designed to deal
with diagnosis matters using morphology and immunophenotyping. This group aimed at …

The systematic modification of natural products through diverted total synthesis is a powerful
concept for the systematic modification of natural products with the aim of studying …

Siglecs (sialic acid-binding Ig-like lectins) are mainly expressed in the immune system. Sn
(sialoadhesin)(siglec-1), CD22 (siglec-2) and siglec-15 are well conserved, whereas the …

Two trivalent constructs consisting of single‐chain Fv antibody fragments (scFvs) specific for
the interleukin‐3 receptor α chain (CD123), CD33 and the Fcγ‐receptor III (CD16) were …

Background Approximately fifty percent of patients with acute myeloid leukemia can be
cured with current therapeutic strategies which include, standard dose chemotherapy for …

Genetic engineering of T cells with chimeric T‐cell receptors (CARs) is an attractive strategy
to treat malignancies. It extends the range of antigens for adoptive T‐cell immunotherapy …

The vast majority of anticancer drugs in clinical use are limited by systemic host toxicity due
to their non-specific side effects. These shortcomings have led to the development of tumour …